Holen Sie sich die Stockscreener-App
74.33
0.62%
-0.46
Handel nachbörslich:
74.33
Schlusskurs vom Vortag:
$74.79
Offen:
$74.54
24-Stunden-Volumen:
1.44M
Relative Volume:
0.63
Marktkapitalisierung:
$12.28B
Einnahmen:
$943.38M
Nettoeinkommen (Verlust:
$-380.99M
KGV:
-30.13
EPS:
-2.4667
Netto-Cashflow:
$-325.67M
1W Leistung:
+2.50%
1M Leistung:
+0.39%
6M Leistung:
+7.69%
1J Leistung:
+174.38%
1-Tages-Spanne:
$73.56
$75.47
1-Wochen-Bereich:
$73.35
$76.48
52-Wochen-Spanne:
$23.95
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
74.33 | 12.35B | 943.38M | -380.99M | -325.67M | -2.4667 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-10-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Hochstufung | Goldman | Sell → Neutral |
| 2025-09-03 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - GlobeNewswire Inc.
Treasury Yields: Can Ionis Pharmaceuticals Inc outperform in the next rallyQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn
IONS PE Ratio & Valuation, Is IONS Overvalued - Intellectia AI
IONS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Ionis Pharmaceuticals repriced drug ahead of key FDA decision, signals push into larger market - MSN
Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by SG Americas Securities LLC - MarketBeat
Retinitis Pigmentosa Market to Reach US$ 26.2 Billion by 2032 - openPR.com
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com
Insider Sell Alert: Shannon Devers Sells Shares of Ionis Pharmac - gurufocus.com
Insider Sell Alert: Shannon Devers Sells Shares of Ionis Pharmaceuticals Inc (IONS) - gurufocus.com
Devers, Ionis Pharmaceuticals EVP, sells $458,613 in IONS stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers Sells 6,193 Shares - marketbeat.com
J. Safra Sarasin Holding AG Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - marketbeat.com
IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
ETF Watch: Can Ionis Pharmaceuticals Inc weather a recessionWeekly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Charcot-Marie-Tooth (CMT) Disease Market Size to Reach US$ - openPR.com
Form 144 | Ionis Pharmaceuticals(IONS.US) Director Proposes to Sell 5.47 Million in Common Stocks - Moomoo
H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Assenagon Asset Management S.A. Cuts Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
The Bull Case For Ionis Pharmaceuticals (IONS) Could Change Following FDA Priority Review For Zilganersen - Sahm
FDA Priority Review Puts Ionis Zilganersen At Center Of Rare-Disease Story - Yahoo Finance
Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report? - Yahoo Finance
Vanguard disaggregates holdings; reports 0 IONS shares (IONS) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Ionis Cuts Tryngolza Price Ahead Of Big New Indication - insights.citeline.com
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market - Benzinga
Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106 - Yahoo Finance
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $106.00 at Barclays - MarketBeat
Barclays Raises Price Target for Ionis Pharmaceuticals (IONS) to $106 | IONS Stock News - GuruFocus
Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp - Barchart
What is HC Wainwright's Estimate for IONS FY2027 Earnings? - marketbeat.com
IONS: HC Wainwright & Co. Raises Price Target to $120 | IONS Sto - GuruFocus
DAVENPORT & Co LLC Purchases 155,334 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Stifel raises Ionis Pharmaceuticals price target on drug pricing By Investing.com - Investing.com Australia
Wolfe Research reiterates Ionis stock rating on pricing strategy - uk.investing.com
Wolfe Research reiterates Ionis stock rating on pricing strategy By Investing.com - Investing.com Australia
Stifel raises Ionis Pharmaceuticals price target on drug pricing - Investing.com
IONS: Needham Raises Price Target for Ionis Pharmaceuticals | IO - GuruFocus
Needham & Company LLC Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $120.00 at HC Wainwright - MarketBeat
Oppenheimer raises Ionis Pharmaceuticals price target on pricing move By Investing.com - Investing.com Canada
Patterns Watch: Why is Ionis Pharmaceuticals Inc stock going upAnalyst Downgrade & Long Hold Capital Preservation Plans - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), GE Healthcare Technologies Inc (GEHC) and Insmed (INSM) - theglobeandmail.com
Aug Big Picture: Does Ionis Pharmaceuticals Inc outperform in volatile marketsSwing Trade & Weekly Chart Analysis and Guides - baoquankhu1.vn
Eugene Schneider reports Common Stock sale notices for IONS (NASDAQ: IONS) - Stock Titan
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - Yahoo Finance
FDA accepts zilganersen application for Alexander disease review By Investing.com - Investing.com Canada
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):